Sapio Sciences makes AI-native drug discovery seamless with Nvidia Bionemo

Sapio Sciences makes AI-native drug discovery seamless with Nvidia Bionemo

The integration of the Nvidia Bionemo platform improves AI capabilities across the drug discovery lifecycle.

SAPIO SCIENCES, THE SCIENCE ANTER™The laboratory informatics platform today announced the integration of the Nvidia Bionemo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into SAPIO ELN (Electronic Lab Notebook) to streamline workflows and improve decision making in drug discovery. The Bionemo platform enables researchers to accelerate drug discovery by leveraging science-specific AI frameworks, advanced models and generative AI tools to optimize the identification of potential drug candidates and improve target selection objectives. Nvidia Bionemo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale.

The integration of Bionemo into the SAPIO platform provides scientists with in silico tools so that they can, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, improve innovation, and accelerate the transition from discovery to development.

Within SAPIO ELN, researchers can access Bionemo NIM microservices to quickly identify and optimize drug candidates using AI-driven molecular modeling, including Alphafold2 NIM to predict accurate 3D protein structures; Moimim nim to enable small molecule design and optimization; and Diffdock nim, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster and more efficient research workflows.

AI innovation is happening rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA's powerful AI-driven tools into the Sapio platform enables researchers to seamlessly apply AI to their experiments. Through this work, we remove inefficiencies and provide scientists with the tools to quickly generate, analyze, and visualize chemical and biological results. “

Kevin Cramer, Founder, CEO & CTO, Sapio Sciences

Kevin continued:"We are working with Nvidia to equip scientists and researchers with the most advanced AI tools to advance innovation in the life sciences. This collaboration is an important step toward making AI an essential part of the drug discovery process, helping researchers make faster, data-driven decisions and improving research results."

Anthony Costa, Director, Digital Biology at Nvidia, commented:"The integration of Bionemo with Sapios' AI-driven research platform provides scientists with access to advanced generative AI models for drug discovery. With Alphafold2, Moimim and Diffdock-NIMs, researchers can predict, optimize and optimize and validate the drug candidates.

Integrating NVIDIA technologies into the Sapio platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics and drug manufacturing.

Sources: